Skip to content
Screener

Iovance Biotherapeutics, Inc. IOVA Business Segments — General And Administrative Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — General And Administrative Expense
$18.61M-16.5%
Immunome logo
IMNMSingle Reportable — General And Administrative Expense
-$8.65M-17.3%
Capricor Therapeutics logo
CAPRSingle Reportable — General And Administrative Expense
$9.4M+54.9%
ALO
ALOVSingle Reportable — General And Administrative Expense
-$658.46K
Research Solutions logo
RSSSSingle Reportable — General And Administrative Expense
$1.63M-11.9%
Ur-Energy logo
URGSingle Reportable — General And Administrative Expense
$3.92M+80.5%

Other financials

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Cash & equivalents$110.8M-16.4%
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation

See full
Market cap$2.77B+222%
Enterprise value$2.71B+247%
P/S8.5×+5.0×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp
FCF margin-91.2%-22.1pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 9:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091716
(in thousands)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Total cost of sales$43,595$48,881$86,093$91,595
Expenses
Research and development$53,773$71,569$111,143$137,619
General and administrative18,61719,66837,31739,524
Sales and marketing15,53611,47230,65224,830
Depreciation and amortization9,5009,35018,03917,415
Other segment items (b)5,60710,67013,85926,114
Total expenses$103,033$122,729$211,010$245,502

Item 1.Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense?
Iovance Biotherapeutics, Inc. (IOVA) reported business segments — general and administrative expense of $18.62M in Q2 2026.
How has Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense changed year-over-year?
Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense decreased by 5.3% year-over-year, from $19.67M to $18.62M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense?
Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense has grown at a -5.8% compound annual growth rate (CAGR), from $78.4M to $69.64M.
What does business segments — general and administrative expense mean?
This covers the overhead costs associated with corporate functions, including legal, human resources, and executive management. It serves as a measure of the company's operational discipline and the efficiency of its administrative support structure.

Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude